$MDXH

Analysts updated price targets for several companies. Baird raised Ross Stores (ROST) target to $270, Parsons (PSN) to $57, and Deere (DE) to $640. BTIG cut Walmart (WMT) target to $140. HSBC raised Ternium (TX) target to $55. Rothschild & Co increased Equifax (EFX) target to $235. Other changes include Envoy Medical (COCH), MDxHealth (MDXH), Hometrust Bancshares (HTB), and Haemonetics (HAE).

MDxHealth reported Q2 2026 revenue of $27.2M, up 16% YoY, with gross profit at $17.9M. Operating loss increased to $5.1M, and net loss rose 36% to $9.5M. The company completed the wind-down of its Resolve UTI business. Management expressed confidence in meeting full-year revenue guidance of $110M-$115M and returning to adjusted EBITDA profitability by year-end, citing growth in its urology and prostate cancer diagnostics.

MDxHealth SA (MDXH) shareholders Laurence W. Lytton and the Lytton-Kambara Foundation filed a Schedule 13G/A reporting beneficial ownership of 18,558,988 and 11,583,098 Ordinary Shares, or 19.5% and 12.1%, respectively, based on 95,417,382 shares outstanding as of Aug. 13, 2026.

MVM Partners, LLC purchased 2,202,643 indirectly-held shares of MDxHealth SA (MDXH) at $0.45 ($1.00M total) on 2026-08-13. Filed jointly with Bednarski Eric (Director).

mdxhealth reported Q2 tissue-based test volume rose 13% sequentially to 12,525 tests, aiding Q2 revenue of $27.2 million, up 16% year over year. Revenue for the first half of 2026 rose 14% to $51.1 million. Liquid Exo mdx volume was 13,578 tests, shifting mix and lowering gross margin to 65.7%. Operating loss widened to $5.1 million. On Aug. 11 it raised $20 million via share placement.

The article highlights microcaps with near-term catalysts. Kartoon Studios (TOON) reported Q2 2026 revenue of about $5.8M and EPS about $0.38, including a $39.2M litigation settlement gain, and said an Amazon Prime Video deal will launch in Feb 2027. SurgePays (SURG) posted Q2 revenue up 40.7% to $16.2M and GAAP net income $1.29M. MDxHealth (MDXH) Q2 revenue rose 16% to $27.2M. IGC Pharma (IGC) expects Phase 2 topline results for IGC-AD1 in Q4 2026.

MDxHealth (NASDAQ: MDXH) reported Q2 2026 revenue of $27.2 million, up 16% year over year and 14% sequentially, and reaffirmed FY26 sales guidance of $110 million to $115 million. Gross profit rose to $17.9 million, but adjusted EBITDA turned negative at -$2.3 million. The company also received a Nasdaq minimum bid notice and raised $20 million via a registered direct placement.

MDxHealth SA (MDXH) reported Q2 2026 revenue up 16% year over year and its largest sequential growth, citing a renewed focus on core urology diagnostics after discontinuing the Resolve UTI business. The company reaffirmed 2026 revenue guidance of $110–$115 million and a return to adjusted EBITDA profitability.

MDxHealth SA said it received another Nasdaq notification letter citing a continued minimum bid price deficiency under Nasdaq rules 5550(b)(2) and 5810(c)(3)(C). Based on market value from June 1 to July 17, 2026, it does not meet the minimum. It has until Dec. 28, 2026 to regain compliance, with shares needing a $1.00 close for 10 days. Stock closed at $0.41.

MDxhealth SA (NASDAQ: MDXH) said Nasdaq notified it on June 30, 2026 that it is not meeting the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The company has until Dec. 28, 2026 to regain compliance by having a $1.00+ closing bid for 10 straight business days. Operations are unaffected; reverse split is possible.